Literature DB >> 24882762

Utility of serum thyroglobulin measurements after prophylactic thyroidectomy in patients with hereditary medullary thyroid cancer.

Carolyn D Seib1, Avital Harari2, Felix A Conte3, Quan-Yang Duh3, Orlo H Clark3, Jessica E Gosnell3.   

Abstract

INTRODUCTION: Prophylactic thyroidectomy can be curative for patients with hereditary medullary thyroid cancer (MTC) caused by RET proto-oncogene mutations. Calcitonin is a sensitive tumor marker used to follow patients. We suggest that thyroglobulin (Tg) levels should also be monitored postoperatively in these patients.
METHODS: We reviewed patients with RET mutations who underwent prophylactic thyroidectomy between 1981 and 2011 at an academic endocrine surgery center. Patients were excluded if they had no postoperative Tg levels recorded.
RESULTS: Of the 22 patients who underwent prophylactic thyroidectomy, 14 were included in the final analysis. The average age at thyroidectomy was 9.8 years (range, 4-29). Tg levels were detectable 1.5 months to 31 years postoperatively in 11 patients (79%), all of whom were <15 years old at thyroidectomy. Median thyroid-stimulating hormone (TSH) was 2.5 mIU/L and 13.4 mIU/L in patients with undetectable and detectable Tg, respectively. Of those with detectable Tg, 5 had cervical ultrasonographic examination: Two showed no residual tissue in the thyroid bed, and 3 showed remnant thyroid tissue.
CONCLUSION: Tg levels can identify patients with remnant thyroid tissue after prophylactic thyroidectomy. Ultrasonography can determine whether thyroid tissue remains posterolaterally that is at risk of MTC recurrence. Maintaining normal TSH may prevent growth of remaining thyroid follicular cells.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24882762      PMCID: PMC4099273          DOI: 10.1016/j.surg.2014.03.037

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  19 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 2.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

3.  A review of 17 cases of medullary carcinoma of the thyroid gland.

Authors:  P W Davis
Journal:  Proc R Soc Med       Date:  1967-08

4.  Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.

Authors:  K Frank-Raue; H Buhr; H Dralle; E Klar; N Senninger; T Weber; S Rondot; W Höppner; F Raue
Journal:  Eur J Endocrinol       Date:  2006-08       Impact factor: 6.664

5.  Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center.

Authors:  González Jose M Rodríguez; María D Balsalobre; Francisco Pomares; Nuria M Torregrosa; Antonio Ríos; Pablo Carbonell; Guillermo Glower; Joaquín Sola; Javier Tébar; Pascual Parrilla
Journal:  J Am Coll Surg       Date:  2002-08       Impact factor: 6.113

Review 6.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.

Authors:  Anna M Sawka; Lehana Thabane; Luciana Parlea; Irada Ibrahim-Zada; Richard W Tsang; James D Brierley; Sharon Straus; Shereen Ezzat; David P Goldstein
Journal:  Thyroid       Date:  2009-05       Impact factor: 6.568

7.  Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study.

Authors:  J A A Meijer; L E H Bakker; G D Valk; W W de Herder; J H W de Wilt; R T Netea-Maier; N Schaper; E Fliers; P Lips; J T Plukker; T P Links; J A Smit
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

8.  Nodular disease and parafollicular C-cell distribution: results from a prospective and retrospective clinico-pathological study on the thyroid isthmus.

Authors:  Giampaolo Papi; Giulio Rossi; Salvatore Maria Corsello; Stefania Corrado; Guido Fadda; Carlo Di Donato; Alfredo Pontecorvi
Journal:  Eur J Endocrinol       Date:  2009-09-30       Impact factor: 6.664

9.  Long-term outcome of "prophylactic therapy" for familial medullary thyroid cancer.

Authors:  Elisabeth Schellhaas; Charlotte König; Karin Frank-Raue; Heinz-J Buhr; Hubert G Hotz
Journal:  Surgery       Date:  2009-07-15       Impact factor: 3.982

10.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging.

Authors:  G Pellegriti; S Leboulleux; E Baudin; N Bellon; C Scollo; J P Travagli; M Schlumberger
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.